Navigation Links
Notre Dame study explores the potential benefits and threats of nanotechnology research
Date:1/25/2013

transmitted between mammalian populations.

After a self-imposed one-year moratorium on this research, several laboratories around the world announced that they will restart the work in early 2013.

The FBI is actively responding to these developments in the scientific community.

"The law enforcement-security community seeks to strengthen the existing dialogue with researchers," William So of the FBI's Biological Countermeasures Unit says in the study.

"Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities[and] create effective safeguards for science and national interests."

The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety aspects of their research and to act to protect society when necessary, argues Eggleson.

"The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity's benefit," she says.

"Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science."


'/>"/>

Contact: Kathleen Eggleson
keggleso@nd.edu
574-631-1229
University of Notre Dame
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Notre Dame researchers demonstrate new DNA detection technique
2. Notre Dame researchers develop paint-on solar cells
3. Nanotrees harvest the suns energy to turn water into hydrogen fuel
4. Notre Dame paper examines nanotechnology-related safety and ethics problem
5. Notre Dame to be part of $194 million university research center network
6. Positive Clinical Study Results for BSPs HyperQ Technology
7. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
8. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
9. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
10. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
11. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 Cytokinetics, Incorporated (Nasdaq: ... first quarter results on Thursday, April 30, 2015 at ... management will host a conference call at 4:30 PM ... the company’s outlook for the future. , The conference ... from the homepage and in the Investor Relations section ...
(Date:4/16/2015)... According to the 2014 Liberty Mutual ... was ranked first among the leading causes of ... pushing, pulling, holding, carrying, or throwing and cost ... Round Company takes statistics like this very seriously. ... develop and design equipment that prevents these injuries ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... , May 18 Caliper Life Sciences, Inc. (Nasdaq: ... and life sciences research, today announced that it reached an agreement to ... evaporation product lines to Biotage AB for $16.5 million in ... "Divesting these ...
... /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" TSX: DDD; OTCBB: ... quarter ended March 31, 2010 . , ... for the Quarter Ended March 31, 2010 , ... The Company recorded $49.06 million of revenues for the quarter ended ...
... ST. LOUIS , May 17 Sigma-Aldrich Corporation (Nasdaq: SIAL ... Thursday, May 20th at 1:15 PM CDT ( 2:15 PM ... audio broadcast over the Internet available at http://investor.sigmaaldrich.com/ .  Users can click ... , , ...
Cached Biology Technology:Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 2Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 4Dragon Pharma reports 2010 first quarter financial results 2Dragon Pharma reports 2010 first quarter financial results 3Dragon Pharma reports 2010 first quarter financial results 4Dragon Pharma reports 2010 first quarter financial results 5Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010 2
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... stroke or who have been diagnosed with Parkinson,s disease, ... Dr Cathy Craig from Queen,s School of Psychology ... those who normally have difficulty controlling their movements. ... 860,924 from the European Research Council. Dr Craig ...
... have discovered two new genes that increase the risk ... While further study is needed to identify the specific ... the genes are particularly strong candidates to be added ... IBD. "As we continue to find genes that interact ...
... reached by the Alliance for a Healthier Generation and ... "competitive foods" such as soft drinks at schools. However, ... availability of soft drinks at school may not be ... In a study of more than 4,000 children, ...
Cached Biology News:New sensory devices will aid Parkinson's and stroke patients 2New genes found for inflammatory bowel disease in children 2New genes found for inflammatory bowel disease in children 3
Hybridization cassette for one slide...
Request Info...
Contains 0.2 g/L EDTA4Na in phosphate-buffered saline....
Quantibody Human Angiogenesis Array 1 (1 slide) Class: Quantitative Antibody Arrays Product Group: Antibody Array...
Biology Products: